Skip to main content

Month: February 2024

AMD Unveils Embedded+ Architecture; Combines Embedded Processors with Adaptive SoCs to Accelerate Time-to-Market for Edge AI Applications

AMD Embedded+ ArchitectureAMD Embedded+ architecture combines AMD Ryzen™ Embedded processors with Versal™ adaptive SoCs onto a single integrated board to deliver scalable and power-efficient solutions that accelerate time-to-market.— AMD-validated solutions provide a simplified path to AI inferencing, sensor fusion, industrial networking, control, and visualization for ODM partners — SANTA CLARA, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced the launch of AMD Embedded+, a new architectural solution that combines AMD Ryzen™ Embedded processors with Versal™ adaptive SoCs onto a single integrated board to deliver scalable and power-efficient solutions that accelerate time-to-market for original design manufacturer (ODM) partners. Validated by AMD, the Embedded+ integrated...

Continue reading

MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS

MangoRx Wants to Keep Fumbles on the Field, Not in the Bedroom, Offering the Losing Team Free MangoRx ED Products for One Year Dallas, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (“GROW”) and erectile dysfunction (“ED”) drug (“Mango”), announces that regardless of who loses the Big Game this Sunday, they are prepared to offer a free one-year supply of its Mango ED products for the entire losing team, ensuring they still get sacked after the game. MangoRx is committed to helping men tackle hard issues. In addition to offering the losing team players the opportunity to score, fans...

Continue reading

Splash Beverage Group, Inc. Secures Major Partnership with Sea World Parks & Entertainment

FORT LAUDERDALE, FL, Feb. 06, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”), a portfolio company of leading beverage brands, today is pleased to announce a significant milestone in its growth journey with the addition of Sea World Parks & Entertainment to its growing list of large venue customers. Sea World Parks & Entertainment, a renowned leader in family entertainment and education, will now offer Splash Beverage Group’s Pulpoloco Sangria in all of its parks across California, Florida, Pennsylvania, Virginia, and Texas. This opportunity supports Splash Beverage Group’s position as a premier provider of high-quality beverages and underscores its commitment to expanding its footprint in key markets. “We are excited to have been...

Continue reading

Bridgetown, Barbados Credit Union Selects BIO-key’s PortalGuard to Enhance Access to Shared Workstations Including Biometrics

BRIDGETOWN, Barbados and HOLMDEL, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of passwordless, phoneless, and token-less Identity and Access Management (IAM) Multifactor Authentication (MFA) solutions, announced that the City of Bridgetown Co-operative Credit Union Ltd. (COB) has selected BIO-key’s PortalGuard platform with Identity-Bound Biometrics (IBB), to transform its secure login methodologies for staff access to critical systems and data. COB has multiple locations supporting more than 60,000 members in Barbados. By implementing BIO-key’s PortalGuard platform with Identity-Bound Biometric authentication, COB ensures a more robust and reliable defense against unauthorized access to the credit union’s systems. Project requirements included meeting or exceeding...

Continue reading

Getty Images Announced as Official Photographer of 2024 Fall/Winter NYFW: The Shows

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, has once again been named as the Official Photographer for the 2024 Fall/Winter Season of IMG’s New York Fashion Week (NYFW): The Shows. As the Official Photographer, Getty Images’ award‑winning entertainment photographers will be delivering high‑quality content throughout New York Fashion Week (February 9-14) in New York City, all to be distributed exclusively through gettyimages.com. This includes covering all shows at RXR’s Starrett-Lehigh building and Fashion Alliance runway shows and presentations, as well as all off-site IMG FOCUS. produced shows, and the first-ever NYFW consumer venue at 21Greene, home to official...

Continue reading

Arhaus Unveils Second Volume of Its Editorial Series Storied, ‘Bellissimo Segreto’

‘Bellissimo Segreto’ – or, “A Beautiful Secret” – pays homage to Arhaus’ artisan partners throughout Italy and the creative process behind the brand’s beloved Italian collectionsArhaus ‘Bellissimo Segreto’Arhaus ‘Bellissimo Segreto’BOSTON HEIGHTS, Ohio, Feb. 06, 2024 (GLOBE NEWSWIRE) — Arhaus (NASDAQ: ARHS), a leader in artisan-crafted and responsibly sourced home furnishings, debuts ‘Bellissimo Segreto,’ the second volume of its editorial series Storied, a compilation of imagery and storytelling developed to commemorate the brand’s artisan partnerships built over the years. Since its inception in 1986, Arhaus has traveled the world to forge enduring relationships with vendors, driven by a commitment to source products directly from the talented craftspeople who create them. In addition...

Continue reading

Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain

First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer On track to commence enrollment in Q1 2024 THE WOODLANDS, TX, Feb. 06, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received authorization from the Uzbekistan Ethics Committee to open the clinical trial site for its proof-of-concept human clinical study evaluating the use of transvascular ablation for the treatment of pancreatic cancer pain. The Company is on track to commence enrollment in the first quarter of 2024. “Our team remains focused on the successful...

Continue reading

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, (doi: 10.1007/s00401-023-02679-6) that provide new insight into the biology of Alzheimer’s disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding.  Using a combination of two high-resolution microscopy techniques: array tomography and Förster resonance energy transfer (FRET), Professor Tara Spires-Jones and colleagues at the UK Dementia Research Institute at University of Edinburgh’s Centre for Discovery Brain Sciences analyzed protein-protein interactions in over 1 million...

Continue reading

ZeroFox to be Acquired by Haveli

ZeroFox announces definitive agreement to be acquired by Haveli Investments for $350M Deal price represents a premium of 45% to the 90-day volume weighted average share price ZeroFox to become a privately held company upon completion of the transaction WASHINGTON, Feb. 06, 2024 (GLOBE NEWSWIRE) — ZeroFox Holdings, Inc. (Nasdaq: ZFOX) (“ZeroFox”), a leading provider of external cybersecurity, today announced that it has entered into a definitive agreement to be acquired by Haveli Investments, a technology-focused private equity firm, in an all-cash transaction with an enterprise value of approximately $350 million. Under the terms of the merger agreement, ZeroFox stockholders will receive $1.14 per share in cash upon completion of the transaction. The per share purchase price represents a premium of 45% over the volume weighted...

Continue reading

DSV, 1089 – SHARE BUYBACK IN DSV A/S

Company Announcement No. 1089 On 1 February 2024, we initiated a share buyback programme, as described in Company Announcement No. 1087. According to the programme, the company will in the period from 1 February 2024 until 23 April 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.78% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day Number of shares bought back   Average transaction price   Amount DKK                        1: 1...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.